SOPHIE SNYDER

Experienced biotechnology leader specializing in Market Access, HEOR, and Data Analytics, with significant experience in cell and gene therapies and oncology and rare disease. I am passionate about improving the use of data and evidence in the pharmaceutical industry to inform policy and enhance patient access. Proven ability to serve as a strategic advisor to senior management, translating complex business problems into actionable insights and data-driven decisions. Strong track record in team leadership and cultivating cross-functional partnerships to expand service capabilities and deliver measurable outcomes.

• Snyder, Sophie, et al. "Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care." Advances in therapy 38.8 (2021): 4541-4555.
• Snyder, Sophie, et al. "Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma." Advances in therapy 38.9 (2021): 4659-4674.
• Snyder, Sophie, et al. "Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis." Forum for Health Economics & Policy. Vol. 1. No. ahead-of-print. De Gruyter, 2020.
• Lyman, Gary H., et al. "Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma." JAMA network open 3.4 (2020): e202072-e202072.
• Fujimoto, J., Tien, D. M., Snyder, S., Hertz, J. A., & Schweitzer, S. (2019). The effect of patent expiration on sales of branded competitor drugs in a therapeutic class. Journal of Generic Medicines, 15(4), 177-184.
• Abramson, Jeremy S., Tanya Siddiqi, Jacob Garcia, Christine Dehner, Andy Nguyen, Sophie Snyder, Matthew Gitlin, and Karen C. Chung. "Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001." (2019): 6637-6637.
• Kalantar-Zadeh, K., Hollenbeak, C. S., Arguello, R., Snyder, S., & Ashfaq, A. (2019). The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD. Journal of medical economics, 1-8.
• Snyder S, Hollenbeak C, Kalantar-Zadeh K, Ashfaq A. “Estimating the Health Economic Outcomes of Serum 25-Hydroxyvitamin D and Intact Parathyroid Hormone Levels in Stage 3-4 CKD: The Impact of Treatment Timing.” FR-PO124. ASN 2018. San Diego, CA, USA.
• Hammes F, Wakeford C, Gitlin M, Snyder S. “Payer and Societal Benefit Of Peginterferon Beta-1a Versus Glatiramer Acetate In Patients With Relapsing-Remitting Multiple Sclerosis In Italy” PND33. 2018, ISPOR Europe 2018, Barcelona, Spain.
• Garcia J, Snyder S, Gitlin M. “A Systematic Literature Review of the Methodological Approaches and Conclusions from Published Cost-Effectiveness Models in the Treatment Of Aggressive B-Cell Lymphomas.” PCN104. ISPOR 2018. Baltimore, MD, USA.
• Garcia J, Snyder S, Gitlin M. “Estimating the Lifetime Costs in Adult Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States.” PCN94 ISPOR 2018. Baltimore, MD, USA.
• Snyder S, Duffant B, Gitlin M. “The Next Level in the Game Of Playing For Formulary Preference.” PCP20. ISPOR 2018. Baltimore, MD, USA.
• Watson C, Gitlin M, Snyder S. “Cost Consequence Analysis of Sc Peginterferon Beta-1a Every 2 Weeks Versus Sc Interferon Beta-1a1w In Patients With Rrms In Five European Countries.” PND26. ISPOR 22nd Annual International Meeting 2017. Boston, MA, USA.
• Pourat, Nadereh, Dana A. Charles, and Sophie Snyder. "Availability of Care Coordination Services and Medical Home Principles Among Those With Chronic Conditions: Measuring Care Outcomes." Medical Care 54.3 (2016): 262-268.
• Charles, Shana Alex, and Sophie Snyder. "The Recession Index: Measuring the Effects of the Great Recession on Health Insurance Rates and Uninsured Populations." California Journal of Politics and Policy 7.2 (2015).
• Lavrardera SA, Snyder S. Health benefits mandates and their potential effects by racial and ethnic groups: Measuring disproportionalities among insured populations. Submitted for the Medical Care program of the 2013 APHA Annual Meeting and Exposition. Boston, MA.
• Lavrardera SA, Snyder S, Ponce N, Kominski G. Before Health Reform Expansion, Public Programs Already Covered One in Five Nonelderly Californians in 2012. Los Angeles, CA: UCLA Center for Health Policy Research, October 2013.
• Lavrardera, S., Snyder, S., & Roby, D. (2012). Health Care Proposals in the 2012 Presidential Campaign. Center for Health Policy Research, University of California Los Angeles, Los Angeles, CA
• Lavrardera, S., & Snyder, S. (2012). Job-based Coverage Insures Less than Half of Nonelderly Californians in 2012. Center for Health Policy Research, University of California Los Angeles, Los Angeles, CA
• Lavrardera SA, Snyder S, and Brown ER. The Effects of the Great Recession on Health Insurance:Changes in the Uninsured Population from 2007 to 2009. Los Angeles, CA: UCLA Center for Health Policy Research, June 2013.
• Lavrardera SA and Snyder S. Three-Fourths of Children and Parents in California’s Building Healthy Communities Sites Eligible for Health Insurance Expansions. UCLA Center for Health Policy Research, Los Angeles, CA: July 2013